Cardiogenic Shock Symposium

 

Funding for this educational activity is provided by ABIOMED



NB. If you have already registered for the Hartzler Symposium and want to apply for the Cardiogenic Shock Symposium, please email hartzlerics@tcc.co.nz rather than using the above link.

Registry evidence suggests that timing of hemodynamic support significantly improves outcomes in patients who present with AMI or AMICGS.  There remains a focus on D2B metrics for these patients, but  studies show that the quality metrics should be changed to Door to Support. Data also demonstrates that developing and following CGS algorithms that specify timing of support also improves outcomes. Widespread adoption of these algorithms may improve survival rates for those in CGS.

This 1/2-day program will focus on presentations, discussions and case reviews that incorporate the following:
- Identifying the patient population that could benefit from early initiation hemodynamic support
- Developing algorithms that incorporate timing, escalation and weaning of hemodynamic support for AMICGS patients
- Best practices for a Heart Team approach

Who should attend these courses?

i. Physicians who currently treat AMICGS patients.
ii. Physicians who would like to refine their treatment strategies for treating these patients and want develop their own algorithms
iii.  Physicians that understand the value of Hemodynamic support and would like to better identify those patients who would benefit from it.

Application & Eligibility

Registration at the Hartzler Interventional Cardiology Symposium is a prerequisite to applying for and attending the "Rationalizing the Timing of Hemodynamic Support in Cardiogenic Shock Symposium". 

Applicants must be advanced operators who use hemodynamic support.

A limited number of educational scholarships are available for applicants that are accepted to attend the Cardiogenic Shock Symposium.  Those applicants will receive a reimbursement scholarship to cover the cost of flight expenses (up to US$750) and accommodation (to the value of Run of House room and tax only) for the nights of Saturday 15 July and Sunday 16 July.   Self-funded applicants can still be accepted to attend once these scholarships have been utilised. 

Reimbursement will be provided upon completion of the course and once travel receipts have been submitted appropriately.

NB. If you have already registered for the Hartzler Symposium and want to apply for the Cardiogenic Shock Symposium, please email hartzlerics@tcc.co.nz rather than using the above link.

Program

Time Topic Speaker
0800 Welcome J. Aaron Grantham
0810 Controversies in Cardiogenic Shock: Data
• The real value of a “p-value”: Statistical Significant vs Clinical Significance
Jeffrey Moses
0830 Management of Shock: What is happening when treating patients with pressors, IABP, Impella and ECMO  
0900 Right Heart Cath: Should every MCS patient have one? Ajay Kirtane
0915 Choosing MCS options in AMI Cardiogenic Shock: Rationale for Impella first Marc Dickstein
0945 Practical Insights for Adding Hemodynamic Support into your Critical Care Path:
The Detroit Cardiogenic Shock Initiative (CSI) experience
William O'Neill
1015 Case Presentations

Tokyo Experience
• Current results and issues of emergency CV care in Tokyo

University of Washington
• When an IABP is not enough

Columbia
• ECMO: When, who and for how long
• Best practices for use and weaning

Henry Ford
• Door to Support improves outcomes

MAHI
• Not your typical shock patient


Morimasa Takayama


James McCabe


A. Reshad Garan



William O’Neill


J. Aaron Grantham
1130 Panel Discussion
Facilitated by J. Aaron Grantham
1200 End of Symposium  

 

© 2017 | Conference is managed by
The Conference Company

Designed & Developed by
72DPI